Crispr Therapeutics AG: Strategic Pipeline Progress and Financial Strength Drive Buy Rating
Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.
bovnews18h
Crispr Therapeutics AG (CRSP) Stock Price Reaches $38.85: What Factors Are Influencing This Level?
Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...
technologynetworks20h
Library of Organoid “Mini-Guts” Helps Identify New Pathways in IBD
Technology Networks spoke with Dr. Thomas Dennison, University of Cambridge, to learn more about the advantages of using ...
precisionmedicineonline22h
Intellia Readying for Commercial Activities, First Product Launch in 2027
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...
The Globe and Mail22h
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
Citing positive developments in its development programs, analysts from a couple of investment banks think CRISPR Therapeutics(NASDAQ: CRSP) could more than double your money in the year ahead. Start ...
STAT23h
Pharmalittle: We’re reading about pharma asking Trump to pause Medicare talks, a Truveta database launch, and more
Several large drugmakers will ask the Trump administration to pause Medicare drug-price negotiations, even as Biden-appointed ...
sicklecellanemianews23h
Orna, Vertex partner on gene-editing therapies for SCD, TDT
Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...